CAMBRIDGE, Mass., May 17, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the land ...

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated (ATTR) amyloidosis.

In total, 655 patients were recruited from 87 centres in 26 countries. The median age was 76.5 years and 92.5% were male. More than three-quarters (77.6%) had heart failure of NYHA class 2 and 40% ...

The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis ...

Narrow-moat Alnylam announced positive top-line results from the HELIOS-B Phase 3 study of its investigational RNAi therapeutic, vutrisiran, to treat patients with ATTR amyloidosis with ...

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated ...

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B ...